Literature DB >> 3511889

Prostaglandin and complement interaction in clinical acute respiratory failure.

G J Slotman, K W Burchard, S A Yellin, J J Williams.   

Abstract

This study investigated the interaction of plasma levels of circulating prostaglandins and activated complement in clinical acute respiratory failure (ARDS). Fifty patients at risk for ARDS were followed up for up to ten days. Arterial blood gases and plasma levels of complement components C3a and C5a, thromboxane B2 (TxB), and prostaglandin 6-keto-F1 alpha (PGI) and granulocyte aggregation (GA) were measured daily. Seventeen patients (34%) developed ARDS, with mortality of 41% vs 23% for patients without ARDS. Compared with patients without ARDS, the ARDS group had significantly increased plasma C3a (1,130 +/- 750 vs 636 +/- 368 ng/mL) and granulocyte aggregation (48 +/- 10 vs 17 +/- 4 percentage of the maximum light transmission [% max T]). Plasma C5a, TxB, or PGI did not change significantly with or without ARDS. No measured variable was significantly associated with mortality. Regression analysis revealed significant correlations between GA, TxB, PGI, and arterial oxygenation. Plasma C3a and GA are increased in ARDS, suggesting systemic complement activation. A complex series of interactions between the prostaglandins, complement, and GA appears to be involved in ARDS.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3511889     DOI: 10.1001/archsurg.1986.01400030025002

Source DB:  PubMed          Journal:  Arch Surg        ISSN: 0004-0010


  5 in total

1.  Complement fragment C3a in plasma of asphyxiated neonates.

Authors:  L Schrod; G Frauendienst-Egger; H B von Stockhausen; M Kirschfink
Journal:  Eur J Pediatr       Date:  1992-09       Impact factor: 3.183

2.  Prospectively validated predictions of shock and organ failure in individual septic surgical patients: the Systemic Mediator Associated Response Test.

Authors:  G J Slotman
Journal:  Crit Care       Date:  2000-09-08       Impact factor: 9.097

3.  Complement activation by recombinant adenoviruses.

Authors:  G Cichon; S Boeckh-Herwig; H H Schmidt; E Wehnes; T Müller; P Pring-Akerblom; R Burger
Journal:  Gene Ther       Date:  2001-12       Impact factor: 5.250

4.  High DSCC1 Level Predicts Poor Prognosis of Lung Adenocarcinoma.

Authors:  Sisi Chang; Yahui Zhu; Yutan Xi; Fuyan Gao; Juanjuan Lu; Liang Dong; Chunzheng Ma; Honglin Li
Journal:  Int J Gen Med       Date:  2021-10-20

Review 5.  Mediators of multiple organ failure.

Authors:  R J Goris
Journal:  Intensive Care Med       Date:  1990       Impact factor: 17.440

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.